Stock Analysis
Medtronic plcMDT
P/E 23.17×· 5Y range 20.58–46.00×· bottom 12% of history
Sector: Healthcare · Industry: Medical Devices
AnalystsBuy34 analystsP/E 23.2× sits at the 12th percentile of its 5.086926762491444-year history.
Cash covers 30% of debt · Q3 2026.
PMP Verdict
Mixed fundamentals, cheap valuation
Strengths
- Quality97
- Financial Health73
Risks
- Growth31
Mixed business trading cheap — priced for skepticism.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓P/E 23.2× at bottom 12% of 5-year history
What's happening with MDT
Profile
Strong earnings quality, valuation and moat; growth lags behind.
How is each axis scored?
- Valuation77/100 · Strong
- P/E vs own history (12th pct)25/25
- FCF yield (5.1%)20/25
- P/S (3.2x)20/25
- EV/EBIT (20.8x)12/25
- Growth31/100 · Weak
- Revenue CAGR (3.5%)6/25
- Net income CAGR (-1.2%)0/25
- EPS CAGR 5Y (-0.0%)0/25
- Fwd implied growth (56.9%)25/25
- Profitability57/100 · Moderate
- ROIC (7.8%)5/25
- ROE (10.7%)12/25
- Net margin (13.9%)20/25
- Operating margin (18.1%)20/25
- Financial Health73/100 · Moderate
- Altman Z (2.87)18/25
- Current ratio (2.54)25/25
- Interest coverage (7.2x)18/25
- Net cash / debt (D/A 22%)12/25
- Quality97/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-7.47)25/25
- FCF conversion (117%)25/25
- Margin stability (σ 2.5%)25/25
- Moat75/100 · Strong
- ROIC >12% years (0/9 yrs)0/25
- Median gross margin (66.5%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 10.4%)25/25
About Medtronic plc
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Show more
Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Headquarters: GALWAY · Employees: 95,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
77B+P/E (TTM)23.2xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 20.6x–46.0x · 12th pct
P/FCF19.8xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield5.1%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 3.3%–5.7% · 86th pct
P/S (TTM)3.23xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 2.7x–5.7x · 18th pct
EV/EBIT20.8xC
Grade C: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 16.7x–41.5x · 13th pct
EV/Sales3.9xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E14.8xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.48xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio2.79C
Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield3.01%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio69.8%C
Grade C: HighDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
57CROIC7.8%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE10.7%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA5.7%C
Grade C: AverageReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin13.9%A
Grade A: HighNet Income / Revenue
Operating Margin18.1%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin65.0%A
Grade A: PremiumGross Profit / Revenue
FCF Margin16.3%A
Grade A: HighFCF / Revenue
True FCF Margin15.0%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
31DRevenue CAGR3.5%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-1.2%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-0.0%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth56.9%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-5.7%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income9.5%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.3%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
73B+Altman Z-Score2.87C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.54xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio1.54xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage7.2xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment3.2yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT2.9xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.57xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.30xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
97A+Piotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-7.47A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion117.2%A
Grade A: StrongFCF / Net Income
Margin Stability2.5%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue5.1%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.41xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
KIIL HARRY SKIP Filed | KIIL HARRY SKIP | SellOpen market sale | -1483 | |
Blomquist Denise L. Filed | Blomquist Denise L. | Gift | -600 | |
Marinaro Michael Filed | Marinaro Michael | Tax withholding | -1084 | |
Thompson Kweli Filed | Thompson Kweli | Grant / award | +49.2K | |
Thompson Kweli Filed | Thompson Kweli | Grant / award | +17.3K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Thompson Kweli Filed | Thompson Kweli | Grant / award | +6.9K | |
Blomquist Denise L. Filed | Blomquist Denise L. | Grant / award | +1.4K | |
Blomquist Denise L. Filed | Blomquist Denise L. | Grant / award | +2.3K |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
75B+ROIC >12% Years0/9 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)66.5%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor10.4%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$4.09
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$6.89
Cash & short-term investments per share (Finnhub)
Book Value / Share$39.24
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$28.07B
Total debt obligations (short + long term)
Cash & Equiv.$8.38B
Cash and short-term investments
Net Debt$19.69B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$48.98B
Shareholders' equity (book value)
Asset / Liability2.16xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$121.26B
Current Market Capitalization
Beta0.60B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jul 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Medtronic plc (MDT)
MDT is down 0.73% at the last close. Medtronic plc meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 2.87 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -7.47 suggests a low likelihood of earnings manipulation.
- Medtronic plc converts about 16% of revenue into free cash flow — strong cash generation.
- Takes ~3.2 years to repay net debt from free cash flow.
- At a valuation score of 77/100, MDT trades near the cheapest end of its own historical range (P/E 23.2).
- The stock currently yields 3.0% in dividends.
See how MDT ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all MDT moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 12 | Pre-market | 90.92 | +2.76% | 2.43 |
| Oct 12 | Regular | 91.52 | +3.44% | 2.96 |
| Oct 12 | After-hours | 92.04 | +4.02% | 3.41 |
| Oct 8 | Regular | 87.86 | +2.75% | 2.39 |
| Oct 8 | After-hours | 87.94 | +2.84% | 2.45 |
Frequently Asked Questions about MDT
What is the current Medtronic plc (MDT) stock price?
MDT is trading at $94.75 at the last market close, down 0.73% on the session. PreMarketPrice tracks MDT pre-market, intraday and after-hours prices.
Is MDT stock a buy right now?
PreMarketPrice's quantitative model rates Medtronic plc's financial health at 73/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is MDT stock overvalued?
Medtronic plc trades at a trailing P/E of 23.2 and our valuation score rates it 77/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Medtronic plc report earnings?
No confirmed earnings date is currently scheduled for MDT. The Earnings section lists recent reports and updates as dates are announced.
What sector does Medtronic plc operate in?
Medtronic plc operates in the Healthcare sector, within the Medical Devices industry. The Related Stocks section lists sector peers for comparison.
What does Medtronic plc do?
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases.
About Medtronic plc (MDT) Stock
Medtronic plc (MDT) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry. As of the latest update, Medtronic plc is trading at $94.75, down 0.73% on the day with a market capitalization of $121.3 billion. The financial health score for MDT is 73/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for MDT stock.
MDT Stock Analysis & Key Metrics
On PreMarketPrice, you can track Medtronic plc (MDT) across multiple dimensions:
- Pre-market price & movement: Real-time MDT stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for MDT with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Medtronic plc across multiple reporting periods.
- Financial health score: A composite score of 73/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for MDT.
- Sector peers: Compare MDT against 6 other healthcare stocks on key financial metrics.
Is MDT a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Medtronic plc (MDT) as an investment. The financial health score of 73/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Medtronic plc (MDT) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.